ESTRO 36 Abstract Book

S558 ESTRO 36 2017 _______________________________________________________________________________________________

side effects can lead to quicker response and thus lower inconvenience of patients. Clinical data as life quality and treatment satisfaction could be used to evaluate and improve the therapy workflow. Regular input of patient- reported outcome or side effects can be used to early detect and document the disease progression. Overall, this patient data can be used for scientific evaluations. Eventually, a mobile app would enhance the patient relation to his treating department as he has permanent contact using the mobile app - a trend also evolving in the medical field. PO-1020 Re-irradiation of Head and Neck Sarcomas: initial results of Protontherapy Center of Trento, Italy I. Giacomelli 1 , D. Scartoni 1 , M. Cianchetti 1 , F. Dionisi 1 , B. Rombi 1 , M. Amichetti 1 1 Azienda Provinciale per i Servizi Sanitari APSS Trento, U.O. di Protonterapia, Trento, Italy Purpose or Objective Radiotherapy for head and neck (H&N) recurrent sarcomas is usually limited by the dose tolerance of critical structures mainly in the skull base. Re-irradiation of such cases is rarely performed in clinical practice. Numerous dosimetric studies have shown that proton therapy (PT) can spare more healthy tissue than conventional X-ray therapy and it can result in fewer side effects. We report the preliminary results in terms of feasibility and tolerance of re-irradiation with PT for recurrent previously irradiated H&N sarcomas . Material and Methods Between November 2015 and September 2016 four patients (pts) with five recurrent H&N Sarcomas were re- irradiated with PT. Histology of the primary lesions were: pleomorphic sarcoma (1), alveolar rhabdomyosarcoma (2), sclerosing rhabdomyosarcoma (1), radiation-induced spindle cell sarcoma (1). Median age at re-irradiation was 30.0 years (range, 29.0-50.0 years). Karnofsky performance status was 90-100. Median interval time between previous radiotherapy and PT was 55.4 months; the median total dose received at the first radiotherapy course was 54.7 Gy (range, 50.4 – 60.0 Gy). Target definition was based on CT and MR imaging. Median CTV volume was 45.36 cc (range, 10.48-132.2 cc) and median PTV volume was 126.4 cc (range, 35.87-277.8 cc). Patients received a median total dose of 60.0 GyRBE (range, 50.0- 60.0 GyRBE), 1.8–2.0 GyRBE per fraction; two pts received also sequential and one concomitant chemotherapy. All pts were treated with active beam scanning PT using 2-3 fields with single field optimization (SFO) technique. Acute and late toxicities were registered according to Common Terminology Criteria for Adverse Events version 4.0. Patients’ quality of life was assessed using the EORTCEORTC QLQ-C30 questionnaire. Results Treatment was well tolerated: all patients completed PT without breaks. Acute Grade 3 cutaneous erythema occurred in four pts . Registered G2 toxicities were fatigue (1) and soft tissue edema (1). Concerning late toxicities, one patient had persistent G1 pain at the site of previous irradiation and in one pt acute G3 skin erythema became G1 chronic dyschromia. At a median follow-up of 7.4 months (range, 1.4-12.7 months), all pts are alive with controlled local and distant disease Conclusion Our preliminary experience shows that PT re-irradiation of recurrent H&N sarcoma is feasible and safe. Longer follow- up and a larger number of patients are needed to definitively assess efficacy and late toxicity.

Conclusion In our patients, there is a significant improvement in late radiation toxicity after HBOT, with the best responses being observed in gastro-intestinal and bone toxicity. PO-1019 Mobile Oncology: Survey with Healthcare Professionals about Telemedicine, mHealth and mobile Apps K. Kessel 1,2 , M. Vogel 1 , F. Schmidt-Graf 3 , S. Combs 2,3 1 Technical University Munich TUM, Department of Radiation Oncology, München, Germany 2 Institute for Innovative Radiotherapy iRT, Department of Radiation Sciences DRS, Neuherberg, Germany 3 Technical University Munich TUM, Department of Neurology, München, Germany Purpose or Objective Mobile applications (apps) are an evolving trend in the medical field. To date, no native mobile applications for smartphones or tablets in an oncological setting exist, which support patients during therapy and follow-up and allow for data analysis and/or direct feedback about therapy parameters. Moreover, there is an ongoing discussion whether such apps are really valuable, and whether healthcare professionals (HCP) will accept their use in clinical day-to-day life. Hence, we analyzed their attitude about telemedicine, mHealth, and mobile apps. Material and Methods We developed an online survey with 24 questions evaluating HCPs’ attitude towards telemedicine and patients using medical mobile apps in general, as well as specified questions on functionality and possible disadvantages of an app. A link to the survey was sent to all HCPs of our hospital via an in-house e-mail distributor and lasted for six weeks. Results A total of 108 HCPs completed the survey. Of all, 88.9% consider telemedicine as useful, 84.3% versus 15.7% support the idea of an oncological app complementing classical treatment. Automatic reminders, timetables, laboratory results, and assessing side effects as well as quality of life during therapy were rated as the most important functions. In contrast, uncertainty regarding medical responsibility (88.2%) and data security (82.3%) were reasons mostly named by critics. The wish for personal contact between HCP and patient (41.2%), missing technical skills (23.5%) and disbelieving in improvements of data documentation (23.5%) are additional reasons. Of all respondents, 77.8% (84/108) believe in a resulting time saving if collected data by an app are available at aftercare check-ups, while 22.2% (24/108) are not convinced of a benefit of app-based patient documentation. Favorable of an alert function due to data input by patients with the need for further clarification are 64.8% (versus 35.2%), 94.3% are willing to contact the patient after notification. Of all, 93.5% support the idea to use collected data for scientific research and 75.0% believe it could be beneficial for the providing hospital. Conclusion The present work shows a great approval for telemedicine, mHealth and apps in oncology amongst HCPs. Assessing

Poster: RTT track: Risk management / quality management